Search research articles
Contact Us
Filters
Showing results (61-70 of 82) with videos related to
Page
of 9
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 9, 2011
Myeloid growth factors
Jeffrey Crawford, Jeffrey Allen, James Armitage, et al.
Blood
|
August 12, 2006
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
Daniel J DeAngelo, Richard M Stone, Mark L Heaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2015
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F
Brady L Stein, Stephen T Oh, Dmitriy Berenzon, et al.
Pediatric Blood & Cancer
|
November 3, 2016
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis
Robert J Arceci, Carl E Allen, Ira J Dunkel, et al.
Blood
|
May 23, 2014
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
Eli L Diamond, Lorenzo Dagna, David M Hyman, et al.
Blood Advances
|
September 11, 2020
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
Stephen T Oh, Moshe Talpaz, Aaron T Gerds, et al.
Haematologica
|
October 21, 2017
Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms
Gabriela S Hobbs, Amritha Varshini Hanasoge Somasundara, Maria Kleppe, et al.
Blood
|
February 16, 2010
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis
Priya Koppikar, Omar Abdel-Wahab, Cyrus Hedvat, et al.
Blood Advances
|
December 20, 2018
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms
Raajit K Rampal, John O Mascarenhas, Heidi E Kosiorek, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 22, 2013
Myeloid growth factors
Jeffrey Crawford, James Armitage, Lodovico Balducci, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 82) with videos related to
Sort By:
Page
of 9
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 9, 2011
Myeloid growth factors
Jeffrey Crawford, Jeffrey Allen, James Armitage, et al.
Blood
|
August 12, 2006
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
Daniel J DeAngelo, Richard M Stone, Mark L Heaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2015
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F
Brady L Stein, Stephen T Oh, Dmitriy Berenzon, et al.
Pediatric Blood & Cancer
|
November 3, 2016
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis
Robert J Arceci, Carl E Allen, Ira J Dunkel, et al.
Blood
|
May 23, 2014
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
Eli L Diamond, Lorenzo Dagna, David M Hyman, et al.
Blood Advances
|
September 11, 2020
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
Stephen T Oh, Moshe Talpaz, Aaron T Gerds, et al.
Haematologica
|
October 21, 2017
Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms
Gabriela S Hobbs, Amritha Varshini Hanasoge Somasundara, Maria Kleppe, et al.
Blood
|
February 16, 2010
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis
Priya Koppikar, Omar Abdel-Wahab, Cyrus Hedvat, et al.
Blood Advances
|
December 20, 2018
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms
Raajit K Rampal, John O Mascarenhas, Heidi E Kosiorek, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 22, 2013
Myeloid growth factors
Jeffrey Crawford, James Armitage, Lodovico Balducci, et al.
Page
of 9